The 99-amino-acid HIV-1 aspartic proteinase was expressed to high levels in Escherichia coli using a T7 expression system. About 50% of the insoluble material after sonication of the bacteria was composed of aggregated proteinase. Subsequent renaturation and purification yielded large quantities of a homogeneous enzyme able to cleave various heptapeptidic substrates in vitro with a K m around 2.5 mM. A fluorometric assay has been devised to allow automated screening of HIV proteinase inhibitors based on an analogous renin assay. We used the synthetic intramolecularly quenched fluorogenic substrate Suc-TLNFPIS-4MCA based on the heptapeptide TLNFPIS, which encompasses the proteinase/reverse transcriptase junction, coupled to the fluorophore 7-amino-4-methylcoumarin and blocked at the amino-terminus by a succinyl group. The enzyme cleaves the substrate between phenylalanine and proline, and conditions were optimized for liberation of 7AMC from the generated PIS-4MCA with aminopeptidase M as secondary enzyme. 7AMC was monitored with a microplate fluorescence scanner. The known aspartic proteinase inhibitor pepstatin A consistently gave I( = 2 x 10-6 M. Other synthetic and natural compounds are currently being tested.
Introduction
The only licensed treatment for the acquire immune deficiency syndrome (AIDS) is the drug 3' -azido-2' ,3'dideoxythymidine (AZl), which acts as an inhibitor of the viral enzyme reverse transcriptase (Furman et al., 1986) . Unfortunately, AZT is very toxic to the bone marrow and induces severe anaemia/leucopenia which often results in discontinuation of the treatment (Doumon et al., 1988) .
Secondly, AZT seems to be rather inefficient in macrophages because of the low level of endogenous kinases required for converting AZT into AZT-triphosphate, which is the active intracellular form (Richman et aI., 1987) . AZT generally fails to maintain remission in patients with AIDS (Bach, 1989) .
One of the other more promising targets in HIV-1 is the proteinase encoded by the 5'-end of the pol reading frame. This enzyme is an aspartic proteinase like renin, for which very potent inhibitors have been designed (Szelkeet al., 1982) . The proteinase is essential for viral replication (Kohl et aI., 1988) and seems to act during, or just after, budding to convert nascent virions into mature infectious virions. Its natural substrates are the gag and gag-pol precursor polypeptides, which include about nine potential cleavage sites and are processed to generate structural (MA, CA, NC p7+p9) and replication (PR, RT, RH, IN) proteins.
Many groups have been involved in producing and purifying this enzyme, either from virions or from recombinant organisms (reviewed in Hostomsky et aI., 1989) or even by chemical synthesis (Nutt et a/., 1988; Schneider and Kent, 1988) , in order to study its biochemical properties and to perform structural analysis. Two groups have recently published the a-carbon structure of crystallized HIV-1 proteinase, in the latter case prepared from chemically synthesized protein Wlodawer et aI., 1989) . However, most expression systems used at present appear rather inefficient and necessitate huge culture volumes to yield a few milligrams of purified enzyme (McKeever et aI., 1989) .
We have achieved high-level production of the proteinase in Escherichia coli. The proteinase was present in an aggregated form which was solubilized in the presence of a chaotropic agent and subsequently renatured by dilution. We used the purified enzyme to design an automated fluorometric assay based on a similar assay devised for renin by Murakami et al. (1981) .This assay is currently used for screening potential HIV-1 aspartic proteinase inhibitors.
Results

Expression
Since a first construction using a pol gene fragment under the control of the P R promoter of phage X. had given a very 
-
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Enzyme purification
The HIV-1 aspartic proteinase, expressed mainly in an aggregated form, was solubilized and denatured in the presence of chaotropic and reducing agents. The main purification step was achieved by gel filtration of the denatured material on a Sephacryl S-200 column (Fig. 3 ). This step resulted in the elimination of more than 85% of the contaminating proteins. Protein concentration was adjusted to 100-150 /Lg mr' and the concentration of the denaturing agent was then reduced by 50-fold dilution, bringing the protein concentration to a final value of 2-3 /Lg ml". Highest renaturation yields thus obtained were in the 30% range. Maximum enzymatic activity (monitored by HPLC; see Materials and Experimental procedures) was obtained in 1-2 hours, and loss of activity was observed after further incubation. As previously described, addition of ethylene glycol and glycerol to the renaturation buffer increases the stability of the protein.
Further purification of the active enzyme was achieved by two ion exchange chromatography steps: Q-Sepharose Fast Flow batch followed by S-Sepharose Fast Flow 15 residues that were obtained were in agreement with the sequence of HIV-1 aspartic proteinase, namely PQITLW-QRPLVTIKI. It can be noted that according toJh~length parameter rule (2nd codon encodes proline), the initiator methionine has been almost completely excised by the endogenous methionyl-aminopeptidase (Hirel et al., \ 1989) . Bg/Tl cPlO low level of expression (results not shown), we decided to use the T7 genetic expression (Rosenberg et al., 1987) system, which had proved its efficiency in the case of Cathepsin D, another proteinase (Udey and Conner, 1988) weakly expressed by conventional constructions. An Nde I site (CATATG) including a start codon was introduced by site-directed mutagenesis at the 5' -end of the proteinaseencoding sequence (isolate LAV s RU ) ' An ochre codon (TAA) and a BamHI site were introduced at the 3'-end of the same structural gene. The resulting Ndel-BamHI fragment was cloned into pET3a, placing the exact 99-codon PR gene under the control of T7 promoter <j J10. The resulting plasmid, pXL1383 ( Fig. 1 ), was introduced into strain BL21(DE3) in the presence or the absence of plasmids pLysS or pLysE, which code for the T7-lysozyme, itself an inhibitor of T7-DNA polymerase. Upon IPTG induction, and mainly in BL21(DE3) pLysS, about 50% of insoluble material remaining after sonication was composed of aggregated HIV-1 proteinase (Fig. 2) . However, about 5% of the total amount of proteinase was found in the cytoplasmic soluble fraction. The proteinase production level was estimated as 6% of total protein by optical densitometry of a Coomassie gel. A Western blot was then performed with a monoclonal antibody raised against a peptide sequence included in the proteinase and provided by K. Moelling (Max Planck Institute, Berlin, FRG). The only band revealed was of the correct molecular weight (1 0 000).To ascertain the identity of this band, it was submitted to NH 2-terminal microsequencing after transfer onto PVDF blotting paper. The FPLC.At pH 9, the protease was not retained by the QSFF resin. The effluent was subjected to chromatography over SSFF resin and the enzymatically active protease was eluted in phosphate buffer at non-optimal pH with a specific activity around 0.1 mol S-1 rnor' in the described assay. The final step, (NH 4hS04 precipitation, was used to remove a persistent contaminant of -18kD.
Fluorometric assay
We first determined the most efficient minimal peptide substrate for the HIV-1 proteinase. Kay (1985) had reported that for most aspartic proteinases the active-site cleft can accommodate seven amino acids in the S4-S'3 subsites. We accordingly synthesized heptapeptides corresponding to the known cleavage sites in the gag and gag-pol precursors. This included SQNYPIV(MAICAjunction) ARLVAEA and ATIMMQR (CAINC junction), PGN-FLQS (p7/p9 junction), SFNFPQI (PR NH 2-terminus), TLNFPIS (PRIRTjunction), LEKEPIV(RT/RHjunction), and RKVLFLD (RT/IN junction). The heptapeptide TLNFPIS (K m = 2mM, K cat = 4.8s-1 ) representing the junction between the proteinase and the reverse transcriptase was one of the most efficient substrates ( Fig. 4) and was used, following the same strategy as described by Murakami and coworkers (1981) , to produce an intramolecularly quenched fluorogenic substrate (Suc-TLNFPIS-4methyl-7coumarin amide). The HIV-1 proteinase cleaves the F-P Fig. 4 . Heptapeptide hydrolysis by HIV-1 aspartic proteinase. 100 nmol of each potential substrate was incubated at 37"C with 0.1 flog of HIV proteinase in 50mM sodium acetate buffer, pH 5.0, containing 1.5mM dithiothreitol. At appropriate times, hydrolysis was stopped by heating at 100°C, and samples were analysed by RP-HPLC (C18, Novapak, Waters). Elution was by a linear gradient of acetonitrile ((}-40%). Peaks of substrates and generated products were quantified by integration of absorbance at 215nm. Two of the candidate heptapeptide substrates, LEKEPIV and ARLVAEA (see text), were not cleaved by the proteinase in this system. bond specifically, thus liberating a free N-terminus which permits a second enzyme, an aminopeptidase, to continue stepwise cleavage, finally liberating the free detectable fluorophore, It was verified by HPLC that deriviatization of TLNFPIS to give Suc-TLNFPIS-MCA did not modify the specificity or the kinetics of the cleavage reaction by the HIV proteinase ( Fig. 5) .
A problem specific to the HIV-1 cleavage site and which was not encountered in the development of similar substrates for renin was the fact that the N-terminal proline generated after the HIV-1 PR reaction is a very poor substrate for most aminopeptidases. A number of aminopeptidases were tested and aminopeptidase M was chosen as the most efficient, permitting acceptable rates of hydrolysis with reasonable quantities of auxiliary enzyme (data not shown).
The problem of poor reactivity of the second enzyme was also resolved to some degree by careful selection of the pH values for the two phases of the reaction, the first phase being performed at pH 5, near the optimum for the HIV-1 proteinase, and the second being performed at pH 7.5, at which pH aminopeptidase M is still significantly active but HIV-1 exhibits insignificant activity (data not shown).
Inhibitors are tested in the same system, with an amount of HIV-1 proteinase (0.15 fL9) which hydrolyses less than 25% ofthe substrate present in the reaction. Incorporation of an additional control is necessary to ensure that the activity of aminopeptidase M (using 10 nmolleucine-MCA as substrate) is not affected by the molecules under test. Reference inhibitor pepstatin A consistently gave K; = 10-6M (data not shown). This simple assay method is rapid, economical with reagents, readily automated, and permits the screening of a large number of inhibitors. 10 nmol ofTLNFPIS orSuc-TLNFPIS-MCA was incubated at 37"C with increasing amounts of proteinase in the same reaction mixture as detailed in Fig. 4 . Reaction was stopped after 1h by heating at 100°C and the percentage hydrolysis of TLNFPIS or Suc-TLNFPIS-MCA was 40 determined by HPLC or fluorimetry, respectively.
The rate and extent of hydrolysis of the two substrates were identical.
Discussion
Our system enables us to produce effectively unlimited quantities of the HIV proteinase, for use in the described screening assay, and in structure/function studies of the proteinase. A number of HIV-1 proteinase inhibitors have been described, including the classical pepstatin A (K; = 10-6 M) and the very potent H261 (K;= 10-9 M in Richards et el., 1989) . Unfortunately, the latter seems to be inefficient in inhibiting viral replication, at least in C8166 cells (Kinchington et aI., 1989 and D. Kinchington, personal communication) and the ability of the former to inhibit the virus in cellular culture is unclear: Von der Helm and collaborators (1989) observed an inhibition at 10-4 M on H9 cells whilst our studies using the CEM13 cell line and others do not reveal any inhibition (results not shown). Efficient anti-AIDS drugs targeted to the proteinase would need to penetrate the cellularlviral membrane as well as inhibit the enzyme. Such molecules may be identified by screening large numbers of molecules of different origins.
It is not essential for a candidate molecule to inactivate the enzyme irreversibly, although this might be preferable, and competitive inhibitors could be effective antiviral agents since virions, if prevented from maturing, rapidly shed gp120 and therefore lose, in a few hours, the ability to bind and infect CD4+ cells (Layne et al., 1989) .
It is reasonable to hypothesize that by combining drugs acting at different levels of the viral cycle, such as reverse transcription, maturation by the proteinase, viral attachment and transactivation, it might be feasible to completely inhibit the viral replication in infected people, in order to allow the immune system to recuperate and control the infection.
Materials and Experimental procedures
GeneHcconslfucHons
Plasmid pBT1 was a generous gift from Mike Emerman (Institut Pasteur, Paris, France). Oligonucleotides for mutagenesis were synthesized on an 8600 DNA synthesizer (Milligen/Biosearch, Burlington, MA) and subsequently purified on acrylamide gel. Site-directed mutaqenesis was performed according to the phosphorothioate method (Nakamaye and Eckstein, 1986) with the kit provided by Amersham (Buckinghamshire, UK). Mutant screening was performed by dot-blot hybridization as previously described (Zoller and Smith, 1983) . Restriction endonucleases were purchased from New England Biolabs (Beverly, MA). Strain BL21(DE3) and plasmids pET3a, pLysE and pLysS were kindly provided by F. W. Studier (Brookhaven National Laboratory, NY).
A 2588 bp BglII-EcoRI fragment from pBT1, containing most of the pol genes, was ligated with the large Pstl-EcoRI fragment of p1C-19H (Marsh et el., 1984) and in the presence of a Pstl-BglII adaptator (an equimolar mixture of oligonucleotides 5'-GATCTTCCCTAAAAAACATATGCTGCA-3' and 3'-AAGGGAT-TTTTTGTATACG-5'). This construction recreates the 5'-end of the pol open reading frame. The resulting plasmid was amplified in E. coli ceoo, digested with Pstl and EcoRV, and a 938bp fragment containing the whole PR gene was ligated into M13tg131. After transformation into E. coli TG1, the resulting vector was used as template for site-directed mutagenesis to introduce an Ndel restriction site at the 5'-end and both a TAA stop codon and a BamHI restriction site at the 3 /-end of the structural gene coding for the HIV-1 aspartic proteinase. Oligonucleotides xol9: 5'-CCAAAGAGTGATCTGAGGCATATGAA AGGATACAGTTCC-3' and xo110: 5'-GGTACAGTTTCAATAGG-GGATCCTTAAAAATTTAAAGTGCAACC-3' were simultaneously used forthis purpose. A 305bp Ndel-BamHI fragmentfrom this double mutant was ligated into plasmid pET3a (Rosenberget al., 1987) and the resulting plasmid, pXL1383, was used to transform E. coli BL21(DE3), B121(DE3) pLysE and BL21(DE3) pLysS. A preculture was grown at 37"C overnight in LB medium (NaCI(5g 1-1 ) , Bacto-Tryptone (10g 1-1 ) and yeast extract (5g 1-1 ) from Difco (Detroit, MI)) containing ampicillin and chloramphenicol, diluted 1/100 in the same medium and cells were grown at 37"C up to OD 6 5 0 = 1. 1 mM IPTG (Bachem A.G., Bubendorf, Switzerland) was then added to the medium and cells were induced for three more hours and harvested by centrifugation.
High-density fermentation
Culture media. Stock cultures were prepared from overnight cultures in LB medium + antibiotics (ampicillin, 100mg 1-1 and chloramphenicol, 100mg 1-1 ) added with 20% glycerol and frozen in liquid nitrogen. Seed-Flask culture medium was M9 medium (Miller et al., 1972) complemented with glucose (5g 1-1 ) , yeast extract (3g 1-1 ) and antibiotics. [3-agarplates (id.) were used for determination of the number of viable cells in the fermentation broth. The fermentation culture medium previously described (Jung et al., 1988) was complemented with ampicillin, chloramphenicol, (100mg 1-1 ) and glucose (33g 1-1 ) + yeast extract (20g 1-1 ) for batch cultures, or glucose (2g 1-1 ) + yeast extract (2g 1-1 ) for fed-batch cultures. The composition of the feed medium was glucose (500g 1-1 ) + MgS0 4 , 7H 20 (7g 1-1 ) during the growth phase and glucose (200g 1-1 ) + yeast extract (from Oto 200g 1-1 ) during the production phase. Induction was achieved by the addition of 1mM IPTGto the medium.
Analytical methods. Cell growth was monitored by optical density at 600 nm and biomass was also estimated from dry pellets and expressed as grams of dry weight per litre. Concentrations of glucose and acetate were determined using the glucostat reagent (Biotrol, Paris, France)and HPLC, respectively. Dissolved oxygen concentration was monitored using an oxygen sensor (ingold, Urdorf, Switzerland).The on-line determinations of O 2 and CO 2 in the exhaust gas were carried using a paramagnetic O 2 analyser OX 1 (Asag/Helios, Therwil, Switzerland) and an infrared CO 2 analyser Binos 100 (Leybold/Heraeus, K51n, FRG). CO 2 evolution (CER) and the oxygen uptake ratio (OUR) were automatically collected and computed. Proteinase expression was assayed by sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining.
Fed-batch. Fermentation was carried out in fed-batch mode in a 2-litre fermentor (SGI, Toulouse, France) or a 20-litre fermentor (LSL-Biolaffite, Saint-Germain-en-Laye, France) initially containing 1 litre or 14 Iitres of fermentation medium, respectively. The inoculum was prepared by aseptically transferring 0.3ml of a frozen stock culture into 500 ml of seed-flask culture medium in a 2-litre flask. Culture was grown overnight at 37"C on a rotary shaker and the fermentors were then inoculated at a rate of 8%. During fermentation, the pH was automatically controlled and adjusted to pH 6.9 with 10% ammonia (wlv). Temperature was maintained at 37"C during both growth and production phases. Following the initial consumption, glucose concentration was maintained below 1g 1-1 by adding the feed medium with a microcomputer-controlled peristaltic pump. The glucose feeding rate was adjusted to prevent acetate formation. Aeration was maintained at 1 vol vor' mlrr' and the dissolved oxygen was controlled at 40-45% air saturation by the impeller speed controller and, when necessary, by gradual enrichment of the air stream by pure O 2 . Foam was suppressed by the addition of antifoam Emkapyl (Dow Chemicals, Houston, TX). All the culture parameters (pH, temperature, agitation, dissolved O 2, O 2 and CO 2 in exhaust gases, CER, OUR and RQ) were collected and analysed by an on-line microcomputer.
Protease purification
Cells were resuspended in 50mM Tris-HCI, pH 8, 1 mM EDTA, 0.02% Triton X-1 00 and frozen at -70°C. Frozen cells (60 g) were thawed in 1 litre of 50 mM Tris-HCI, pH 8,1 mM EDTA and lysed in a French press at a pressure of 7 x 10 4 kPa.
The lysate was centrifuged for 15 min at 10000 x g. After washing, the pellet was dissolved in 6 M guanidium hydrochloride, 50 mM Tris-HCI, pH 8, 0.1 M f3MEand chromatographed over a Sephacryl S-200 HR column (5 x 90cm; Pharmacia, Uppsala, Sweden) equilibrated with the same buffer. The optical density of the effluent was monitored at 280 nm. Fractions containing the denatured proteinase were pooled and diluted 50-fold in the renaturation buffer (50mM Tris-HCI, pH 8, 1 mM EDTA, 100mM NaCI, 1 mM DlT, 10% ethylene glycol, 3% glycerol). The dilution was incubated at 4°C for 1-2 hours. The solution was then adjusted to pH 9 and loaded on to Q-Sepharose Fast Flow ion exchange (Pharmacia LKB, Uppsala, Sweden) using a batch procedure. The unbound material was adjusted to pH 5 and applied to an S-Sepharose Fast Flow ion exchange column (5 x 4.2cm; Pharmacia LKB) equilibrated with 50mM citric acid, 50mM Na 2HP04, pH 5, 1 mM EDTA. The column was washed with the same buffer and then with 50mM Na2HP04-NaH2P04, pH 8, 1 mM EDTA and the proteinase was eluted with the same buffer containing 200mM NaCI. In the last purification step, a high molecular weight contaminant was eliminated by 20% (vlv) ammonium sulphate precipitation.
Purified proteinase was stored at -70°C in the presence of 40% (v/v) glycerol. Its purity was assayed at each step by SDS-PAGE analysis and reverse phase high-pressure liquid chromatography (HPLC) on a 100 x 4.6mm Aquapore butyl column (Brownlee Labs, Santa Clara, CAl. Protein concentration during purification was also determined by analytical HPLC. The concentration of the pure product was measured by total amino acid analysis on a PicoTag apparatus (Waters/Millipore, Milford, MA).
Enzyme assay
Different substrates were used for HPLC assessment of the enzymatic activity of the proteinase (ct. Results) including heptapeptide TLNFPIS, decapeptide VSFNFPQITL (KraOsslich et al., 1989) and dodscapeptlde YVSQNFPIVQNR (Richards et a/., 1989) . Peptides were purchased from either Cambridge Research Biochemicals (Cambridge, UK) or Neosystem (Strasbourg, France) or were synthesized on a 431A peptide synthesizer (Applied Biosystems, Foster City, CAl. Peptides were incubated with pure HIV-1 proteinase at pH 5 and the reaction was followed by reverse-phase HPLC analysis of the hydrolysis products on a C18 Novapak column (Waters/Millipore, Milford, MA) with a gradient of 0-40% acetonitrile in 0.07% TFA at a flow rate of 1 ml rnln".
The two-stage fluorescence assay used SuC-TLNFPIS-4MCA (Cambridge Research Biochemicals) in the first step, followed by aminopeptidase M (Boehringer, Mannheim, FRG) release of the fluorescent AMC group.
Assays were carried out in a 96-well black fluoroplate (Labsystem, Helsinki, Finland). The first reaction used 10 nmol of Suc-TLNFPIS-MCA in 50mM acetate buffer, pH 5, BSA (100fL9 mr") and 0.05 to 1 fL9 of HIV-1 proteinase in a total reaction volume of 100 ul, Plates were incubated for 1 hour at 37°C. The second reaction was then initiated by addition of 100 fLlof 100 mM Tris/HCI pH 7.5 buffer containing 2 mM MnCI 2, 100 fLg mr" BSA and 55 mU aminopeptidase M (leucine 4-nitroanilide as substrate). Full development was obtained after 3 hours of incubation at 37"C. Fluorescence was recorded on a Titertek Fluoroscan II microplate fluorimeter (Flow Laboratories, McLean, VA) against a blank without HIV-1 proteinase. Excitation was at 355nm and AMC fluorescence was measured at 460nm.
